Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 08 - 10 entities : Bristol-myers squibb company save search
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-10 (Crawled : 23:00) - biospace.com/
GNMSF | $290.38 220
|
Health Technology
|
| O: -0.39%
H: 5.07%
C: -0.05%
BOLT | $1.14 5.1K
|
|
| O: 3.07%
H: 8.51%
C: 7.23%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.32%
H: 0.16%
C: -0.45%
GMAB | $28.67 1.2% 41K
|
Health Technology
|
| O: 2.33%
H: 0.64%
C: -0.72%
update results
Global Kidney Cancer Drugs Market to Surpass US$ 9.60 Billion by 2030 - Coherent Market Insights
Published: 2022-08-10 (Crawled : 18:00) - prnewswire.com
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.32%
H: 0.16%
C: -0.45%
EXEL | $22.46 -0.13% 320K
|
Health Technology
|
| O: 3.13%
H: 0.69%
C: -10.22%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.58%
H: 1.06%
C: 0.91%
global kidney cancer market
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
Published: 2022-08-10 (Crawled : 12:00) - biospace.com/
TSVT | $4.6 -0.86% 130K
|
|
| O: 6.29%
H: 6.37%
C: -2.99%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.32%
H: 0.16%
C: -0.45%
topline trial results
Gainers vs Losers
| 81% | 19% |
Top 10 Gainers
AGBA | News | $1.37 242.5% 76M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.73 41.22% 46K
|
n/a
ZCMD | $1.98 36.55% 27M
|
Commercial Services
RWOD | $10.61 32.68% 5.1M
|
n/a
PAPL | $2.07 26.22% 550K
|
AULT | $0.304 25.57% 47M
|
Manufacturing
WISA 4 | $7.19 22.07% 18M
|
Electronic Technology
MCB 4 | $39.53 19.43% 88K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.